{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:55:50Z","timestamp":1792716950694,"version":"4.5.0"},"reference-count":20,"publisher":"American Society for Microbiology","issue":"2","license":[{"start":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T00:00:00Z","timestamp":1739404800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T00:00:00Z","timestamp":1739404800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2025,2,13]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:sec>\n            <jats:title\/>\n            <jats:p>\n              Ceftobiprole was recently approved by the United States (US) Food and Drug Administration (FDA) for the treatment of adult patients with\n              <jats:italic>Staphylococcus aureus<\/jats:italic>\n              bacteremia, including right-side endocarditis, acute bacterial skin and skin structure infections, and community-acquired bacterial pneumonia in adults and pediatrics. Ceftobiprole is an advanced-generation cephalosporin approved in many countries for the treatment of adults with community-acquired pneumonia and hospital-acquired pneumonia, excluding ventilator-associated pneumonia. We evaluated the activities of ceftobiprole and comparators against methicillin-resistant\n              <jats:italic>S. aureus<\/jats:italic>\n              (MRSA) and multidrug-resistant (MDR)\n              <jats:italic>S. aureus<\/jats:italic>\n              clinical isolates. A total of 19,764\n              <jats:italic>S<\/jats:italic>\n              .\n              <jats:italic>aureus<\/jats:italic>\n              isolates were collected from patients with various infection types at 37 US medical centers from 2016 to 2022. Susceptibility testing was performed by broth microdilution according to Clinical and Laboratory Standard Institutes (CLSI) standards. Isolates were categorized as MDR if they were nonsusceptible by CLSI criteria to \u22653 antimicrobials. Ceftobiprole was highly active against MRSA (\n              <jats:italic>n<\/jats:italic>\n              = 8,184; MIC\n              <jats:sub>50\/90<\/jats:sub>\n              , 1\/2 mg\/L; 99.3% susceptible [S]) and MDR (\n              <jats:italic>n<\/jats:italic>\n              = 2,789; MIC\n              <jats:sub>50\/90<\/jats:sub>\n              , 1\/2 mg\/L; 98.1%S) isolates and retained activity against 87.3% of ceftaroline-nonsusceptible isolates (\n              <jats:italic>n<\/jats:italic>\n              = 433; MIC\n              <jats:sub>50\/90<\/jats:sub>\n              , 2\/4 mg\/L). Ceftobiprole demonstrated greater susceptibility rates than ceftaroline against all resistant subsets. Ceftobiprole was highly active against isolates nonsusceptible to clindamycin (98.0%S), daptomycin (100.0%S), doxycycline (98.2%S), erythromycin (99.5%S), gentamicin (98.1%S), levofloxacin (99.1%S), tetracycline (99.1%S), tigecycline (100.0%S), and trimethoprim-sulfamethoxazole (99.4%S) and isolates with decreased susceptibility to vancomycin (98.3%S).\n            <\/jats:p>\n          <\/jats:sec>","DOI":"10.1128\/aac.01402-24","type":"journal-article","created":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T14:00:27Z","timestamp":1736776827000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":9,"title":["Ceftobiprole activity against multidrug-resistant\n            <i>Staphylococcus aureus<\/i>\n            clinical isolates collected in the United States from 2016 through 2022"],"prefix":"10.1128","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7022-6644","authenticated-orcid":true,"given":"Helio S.","family":"Sader","sequence":"first","affiliation":[{"name":"JMI Laboratories, Element Materials Technology","place":["North Liberty, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer I.","family":"Smart","sequence":"additional","affiliation":[{"name":"Basilea Pharmaceutica International Ltd","place":["Allschwil, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo E.","family":"Mendes","sequence":"additional","affiliation":[{"name":"JMI Laboratories, Element Materials Technology","place":["North Liberty, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Castanheira","sequence":"additional","affiliation":[{"name":"JMI Laboratories, Element Materials Technology","place":["North Liberty, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics12030557"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofy270"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01043-17"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2300220"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.01648-22"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics10020170"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2019.01.015"},{"key":"e_1_3_2_9_2","volume-title":"M07Ed11. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically","author":"CLSI","year":"2018","unstructured":"CLSI. 2018. M07Ed11. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Wayne, PA."},{"key":"e_1_3_2_10_2","volume-title":"M100Ed34. Performance standards for antimicrobial susceptibility testing: 34th informational supplement","author":"CLSI","year":"2024","unstructured":"CLSI. 2024. M100Ed34. Performance standards for antimicrobial susceptibility testing: 34th informational supplement. Wayne, PA."},{"key":"e_1_3_2_11_2","unstructured":"US FDA. 2024. US FDA-recognized antimicrobial susceptibility test interpretive criteria. Washington D.C. Available from: https:\/\/www.fda.gov\/drugs\/development-resources\/antibacterial-susceptibility-test-interpretive-criteria"},{"key":"e_1_3_2_12_2","unstructured":"EUCAST. 2024. Breakpoint tables for interpretation of MIC\u2019s and zone diameters version 14.0. Available from: https:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Breakpoint_tables\/v_14.0_Breakpoint_Tables.pdf"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlac030"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S176369"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01566-18"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1177\/10600280221082326"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw282"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M112.355644"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dks069"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2023.106883"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics12121692"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.01402-24","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.01402-24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T15:05:41Z","timestamp":1739459141000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/aac.01402-24"}},"subtitle":[],"editor":[{"given":"Benjamin P.","family":"Howden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,2,13]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2,13]]}},"alternative-id":["10.1128\/aac.01402-24"],"URL":"https:\/\/doi.org\/10.1128\/aac.01402-24","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,13]]},"assertion":[{"value":"2024-09-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01402-24"}}